Key facts
- European Commission approved AbbVie's Aquipta (atogepant).
- Aquipta is for the acute treatment of migraine in adults.
- The approval offers a new treatment option for migraine sufferers in Europe.
Migraine is a debilitating neurological condition affecting millions worldwide. The approval of Aquipta by the European Commission signifies a potential advancement in managing acute migraine attacks, offering a new therapeutic option for patients in the European market.